Can systemic inflammation promote vascular retention and inflammatory modification of ApoB-containing lipoproteins?

Systemic inflammation, characterized by elevations in high-sensitivity C-reactive protein (hs-CRP) and ferritin, actively drives cardiovascular risk by altering the physiological behavior of apolipoprotein B (ApoB)-containing lipoproteins within the arterial wall. This process facilitates a transition from simple lipid accumulation to progressive atherosclerosis.

Mechanisms of vascular retention

• Endothelial Transcytosis: Elevated hs-CRP directly stimulates the transcytosis of LDL particles across the endothelial barrier and into the vascular wall.
• Ionic Binding: Within the subendothelial space, localized inflammation and acidosis modify ApoB to enhance its positive charge, strengthening its ionic binding to negatively charged arterial proteoglycans.
• Enzymatic Modification: Inflammatory enzymes, including secretory phospholipase A2 (sPLA2) and mast cell proteases, alter ApoB and proteoglycans, facilitating hyper-binding and prolonged vascular retention.

Inflammatory modification and feed-forward cascades

• Oxidative Modification: Trapped ApoB-containing lipoproteins are highly vulnerable to local oxidation. Elevated ferritin, which correlates with hs-CRP and LDL, drives iron-mediated oxidative stress to convert sequestered LDL into highly atherogenic oxidized LDL (oxLDL).
• ROS Production: This modification is accelerated by hs-CRP, which amplifies endothelial reactive oxygen species (ROS).
• Inflammatory Amplification: Modified oxLDL acts as a potent inflammatory stimulus that activates endothelial cells and recruits monocytes, establishing a self-reinforcing feed-forward loop that amplifies vascular and systemic inflammation.

Bottom line

• Systemic inflammation marked by elevated hs-CRP and ferritin acts as a key driver of atherogenesis by promoting a pathogenic feed-forward cycle: inflammation accelerates the vascular retention of ApoB-containing lipoproteins, which undergo rapid oxidative modification to further fuel systemic cardiovascular disease.